GW Pharmaceuticals cannabis-based spray boosts their European expansion

As reported by Business Week, the Cambridge-based, GW Pharmaceuticals Plc’s,  Sativex is speeding their expansion into Europe.

Sativex is a cannabis-based medical oral spray, which has been approved in Spain, New Zealand and Canada to treat the symptoms of multiple sclerosis.  However, the pharmaceutical company are now looking to expand sales in 10 new European countries.

The drug is currently used in the treatment of MS but the product is now about to complete Phase III clinical trials as a treatment for cancer.

Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs now.

Posted in: Featured Jobs, News
CK Logo in place of featured image